Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

AI-Enabled Drug Discovery and Clinical Trials market is projected to grow at a CAGR of 26.5% by 2033: Visiongain

Published

on

Visiongain has published a new report entitled AI-Enabled Drug Discovery and Clinical Trials Market Report 2023-2033: Forecasts by Components (Services, Software), by Application (Clinical Trials, Drug Design, Data Aggregation and Analysis, Drug Characterisation, Biomarker Research, Others), by Therapeutic Area (Oncology, Cardiovascular Diseases, Infectious Diseases, Neurodegenerative Diseases, Metabolic Diseases, Others), by End-user (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organisations (CROs), Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis.

The AI-enabled drug discovery and clinical trial market was valued at US$1,756.4 million in 2022 and is projected to grow at a CAGR of 26.5% during the forecast period 2023-2033.

Growing Awareness of AI in Healthcare is Propelling the Market Growth
As the utilization of AI in healthcare services continues to expand, there has been an increase in public awareness and acceptance of AI-enabled solutions. Consequently, pharmaceutical companies are actively seeking to integrate these solutions into their drug discovery and clinical trial processes. Within the pharmaceutical industry, AI-based drug delivery solutions are gaining significant popularity. These solutions leverage artificial intelligence technologies to develop more efficient and effective methods of drug delivery. The application of AI in drug delivery holds immense transformative potential, including cost reduction, enhanced drug efficacy and safety, and improved patient outcomes. By harnessing AI, the pharmaceutical industry is poised to experience a remarkable shift in drug delivery practices. For example, Novartis is one of the leading players in the AI-based drug delivery market, with a focus on developing smart inhalers to treat respiratory diseases. Also, Insilico Medicine is a drug discovery company that is using AI to develop new drugs and drug delivery methods.

Download Exclusive Sample of Report
https://www.visiongain.com/report/ai-enabled-drug-discovery-market-2023/#download_sampe_div

How has COVID-19 had a Positive Impact on the AI-Enabled Drug Discovery and Clinical Trials Market?
The AI-enabled drug discovery and clinical trial market has experienced a positive impact from the COVID-19 pandemic. The COVID-19 pandemic has created an urgent imperative to find effective treatments and vaccines. Consequently, there has been a surge in the demand for AI-enabled drug discovery solutions due to their ability to expedite the drug development process. Furthermore, the pandemic has accelerated the adoption of virtual clinical trials, which heavily rely on AI-enabled solutions for virtual screening, patient selection, and remote monitoring. Even as the pandemic subsides, the reliance on AI-enabled clinical trial solutions is expected to persist, resulting in an increased demand for such solutions.

How will this Report Benefit you?
Visiongain’s 267-page report provides 102 tables and 151 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the AI-enabled drug discovery and clinical trial market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for AI-Enabled Drug Discovery and Clinical Trials. Get financial analysis of the overall market and different segments including component, application, therapeutic area, and end-user and capture higher market share. We believe that there are strong opportunities in this fast-growing AI-enabled drug discovery and clinical trial market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Cost-effectiveness of AI-enabled Solutions is Boosting its Adoption in Clinical Trials and Drug Discovery
AI-enabled solutions offer the potential to reduce both the time and cost associated with clinical trials. By improving patient stratification and selection, expediting recruitment, and conducting more accurate data analysis, these solutions can enhance the drug development process while mitigating financial risks for pharmaceutical companies. Furthermore, as diseases become increasingly complex, advanced research and development methods are necessary. AI-enabled solutions can aid pharmaceutical companies in addressing such complexities by leveraging big data analysis, identifying biomarkers, and developing novel therapies. Regulatory bodies are placing growing emphasis on the utilization of advanced technologies in drug discovery and clinical trials. Failure to adopt these technologies may result in non-compliance with regulatory requirements.

Improved Patient Outcomes Boosting the Global Market Growth
AI-driven drug delivery and clinical trial solutions have the capacity to enhance patient outcomes by providing personalized treatment plans, advanced analytical capabilities, and real-time patient monitoring. The use of AI-enabled drug discovery solutions holds immense potential to revolutionize the healthcare industry, ultimately improving patient outcomes by facilitating faster and more accurate identification of potential drugs. For instance, AI algorithms can analyze vast volumes of data from scientific literature and clinical trials to uncover new compounds that may exhibit effectiveness in treating various diseases. Notably, Atomwise, a company specializing in AI-driven drug discovery, employed its technology to identify a potential drug for Ebola that had already received approval for other purposes. This discovery prompted the initiation of clinical trials utilizing the repurposed drug for the treatment of Ebola. Such improved patient outcomes are expected to drive the global market growth.

Get Detailed ToC
https://www.visiongain.com/report/ai-enabled-drug-discovery-market-2023/

Where are the Market Opportunities?

Increased Adoption Of AI-Enabled Solution By Pharma & Biopharma Companies For Clinical Trials
Clinical trials play a pivotal role in the development and commercialization of new products for pharmaceutical and biopharmaceutical companies. These trials are conducted to assess the safety and efficacy of drug molecules, and the entire research and development process for a single drug can take over a decade and cost more than a billion dollars before it can be brought to market. However, the success rate for such lengthy clinical trials is relatively low, with less than 10% of them ultimately proving successful.

This application of AI in clinical trials holds the potential to streamline the process and improve its efficiency, ultimately contributing to more effective and successful trials. By leveraging AI-driven data analysis and decision-making, pharmaceutical companies can optimize various critical elements of clinical trials, enhancing the likelihood of successful outcomes and potentially reducing the time and cost associated with drug development.

Competitive Landscape
The major players operating in the AI-enabled drug discovery and clinical trial market are AbbVie Inc., Exscientia, GNS Healthcare, IBM Watson, Merck & Co., Inc., Novartis AG, PathAI, Saama Technologies, and Unlearn.AI, Inc.. The major participants in this market have implemented a variety of approaches, encompassing mergers and acquisitions, investments in research and development, collaborations, partnerships, regional business expansion, and the introduction of innovative products.

Recent Developments

  • In April 2023, Agilent and PathAI joined forces to provide AI-driven assay development solutions for biopharmaceutical research and clinical applications. This collaboration enables the integration of assays and machine learning algorithms into companion diagnostic (CDx) development, resulting in comprehensive and integrated solutions.
  • In November 2022, BigHat Biosciences partnered with Merck Research Laboratories to leverage their proprietary artificial intelligence technologies. This collaboration aims to develop candidates for up to three drug discovery programs, harnessing the power of advanced AI technologies provided by BigHat Biosciences.

To access the data contained in this document please email [email protected]
Avoid missing out by staying informed – order our report now.

To find more Visiongain research reports on the Pharma sector, click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: [email protected]

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent market intelligence providers around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with a lot of synergies. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customised and syndicated market research reports offer a bespoke piece of market intelligence customised to your very own business needs.

Contact
Visiongain Reports Limited
Telephone: +44 (0) 20 7336 6100
Email: [email protected]
Web: www.visiongain.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Rainbow Robotics begins pre-orders of Bimanual Mobile Manipulator RB-Y1, the world’s first research platform for AI experts for $80,000 USD

Published

on

rainbow-robotics-begins-pre-orders-of-bimanual-mobile-manipulator-rb-y1,-the-world’s-first-research-platform-for-ai-experts-for-$80,000-usd

DAEJEON, South Korea, May 9, 2024 /PRNewswire/ — Rainbow Robotics(CEO Jungho Lee), a robot platform specialized company, will begin pre-orders for the Bimanual Mobile Manipulator RB-Y1 from May 8.

During the pre-order period, the research platform is sold for $80,000 USD and the commercial platform is sold for $120,000 USD (VAT excluded). Products are scheduled to be delivered sequentially starting in October.
RB-Y1 is a research platform that has both arms with 7 degrees of freedom per arm for smooth movements similar to human movements. It is a humanoid-like robot with a single leg with 6 degrees of freedom on a mobile platform for a wide work radius. The LiDAR system is adopted for autonomous movement, and a high-performance 3D recognition sensor and master ARM are provided as options to increase usability. In line with the recent trend of the AI era, Rainbow Robotics plans to provide various APIs and options so that AI developers can easily utilize them for research purposes.
Recently, various organizations are introducing humanoid robots. However, they are only used for their own purposes and there is no standard platform for various AI robot researchers. Rainbow Robotics’ RB-Y1 is the first to commercially sell such a research platform.
Unlike existing simple industrial robots, a Bimanual Mobile Manipulator is a humanoid robot that uses both arms and is suitable for advanced manufacturing sites and services. It is a next-generation robot platform that can be used for complex assembly, manufacturing, and collaboration beyond existing simple automation processes.
If you would like to pre-order RB-Y1, please contact us through enquiry page or email us at [email protected].
Meanwhile, Rainbow Robotics will participate as a bronze sponsor in the IEEE International Conference on Robotics and Automation (ICRA 2024), which will be held at Pacifico Yokohama, Japan on May 13.
During the exhibition, various demonstrations will be shown of controlling RB-Y1 with real-time remote operation technology, which links the data arm and simulation system. Additionally, Rainbow Robotics plans to exhibit the small, high-precision collaborative robot RB3-730 and the quadruped robot RBQ-10.
Photo – https://mma.prnewswire.com/media/2407480/Caption___Rainbow_Robotics_Press_Release__Rainbow_Robotics_begins_pre_orders_of_Bimanual_Mobile_Mani.jpg

View original content:https://www.prnewswire.co.uk/news-releases/rainbow-robotics-begins-pre-orders-of-bimanual-mobile-manipulator-rb-y1–the-worlds-first-research-platform-for-ai-experts-for-80-000-usd-302139719.html

Continue Reading

Artificial Intelligence

AgriBusiness Global™ Announces 2024 Event Line-Up: Connecting Crop Input Leaders Worldwide

Published

on

agribusiness-global™-announces-2024-event-line-up:-connecting-crop-input-leaders-worldwide

WILLOUGHBY, Ohio, May 8, 2024 /PRNewswire/ — AgriBusiness Global, the premier business source for leaders in the global crop input value chain, is thrilled to announce its lineup of events for 2024. For 37 years, AgriBusiness Global has been the go-to resource for quality, trustworthy information and analysis, leading the industry in providing the next generation of crop solutions covering synthetic crop protection, biologicals, and plant health.

In 2024, AgriBusiness Global will host three events, each designed to connect industry leaders, promote innovation, and drive business growth:
AgriBusiness Global℠ LATAM Conference Date: 14-15 MayLocation: Panama City, Panama
Capitalizing on Emerging Technologies in LATAM
The ABG LATAM Conference will bring together industry experts and influencers to discuss the latest trends and developments in crop protection, plant health, biologicals, and ag technology specific to the Latin American region. The Latin-American market offers new opportunities for business growth and partnerships with leading players in the region. Learn More>
AgriBusiness Global℠ Trade Summit Date: 7-8 AugustLocation: Orlando, Florida, USA
The #1 Global Agribusiness Event- Dedicated to Worldwide Networking and New Business Development               
The ABG Trade Summit is the trusted forum for advancing development in the rapidly emerging global crop protection, ag tech, plant health, and biological sectors. Attendees can expect to meet with the world’s leading manufacturers, exporters, trading companies, sellers, formulators, and consultants.  Trade Summit facilitates global trade by offering educational sessions, a robust exhibit floor, private meeting rooms, and dedicated networking opportunities for the world market to connect, engage, and build business. Learn More>
AgriBusiness Global℠ SE Asia ConferenceDate: 6-7 NovemberLocation: Jakarta, Indonesia
Empowering Southeast Asia’s AgriBusiness for Global Impact
The ABG Southeast Asia Conference, produced in cooperation with the Indonesian CropCare Association, will showcase cutting-edge technologies and innovations in crop production, addressing the unique challenges and opportunities in the Southeast Asian market. Attendees will gain unique insights to prepare for the future and navigate the present in the rapidly evolving agricultural market. Learn More>
“Our events are dynamic platforms for industry leaders to connect, collaborate, and drive innovation,” said Eric Davis, Group Director at AgriBusiness Global. “We are excited to bring together the brightest minds in the industry to explore new ideas, foster partnerships, and shape the future of agriculture.”
For information about the 2024 events and how to participate, visit AgriBusinessGlobal.com.
About Meister Media Worldwide
For media inquiries, please contact:Amy Reddington, Show Director
Logo – https://mma.prnewswire.com/media/2080421/4694823/Meister_Media_Worldwide_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/agribusiness-global-announces-2024-event-line-up-connecting-crop-input-leaders-worldwide-302140221.html

Continue Reading

Artificial Intelligence

Economic Shifts Ahead as AI Integrates Deeply into Work and Society, Fueling $4.4 Trillion Growth

Published

on

economic-shifts-ahead-as-ai-integrates-deeply-into-work-and-society,-fueling-$4.4-trillion-growth

USA News Group News Commentary
Issued on behalf of Scope AI Corp.
VANCOUVER, May 8, 2024 /PRNewswire/ —  USA News Group News Commentary – New developments in AI technology are currently changing the face of work, economies, and society as we know it, according to analysts at McKinsey & Company who are projecting generative AI (gen AI) could add $4.4 trillion annually to the global economy. Between January and March of this year alone, the world’s largest cloud-computing giants have collectively invested $40 billion mostly into data centres equipped to deal with growing AI workloads, according to The Economist. The shift is leading experts to witness how AI companies are leading a transition from Software-as-a-Service to Service-as-Software, turning the table on the very essence of SaaS, representing a $4.6 trillion opportunity. A variety of tech companies have recently advanced the integration of AI, providing swift, safe, and cost-effective solutions for businesses to adopt artificial intelligence technology this past week, including: Scope AI Corp. (CSE: SCPE) (OTCQB: SCPCF), Meta Platforms, Inc. (NASDAQ: META), Amazon.com, Inc. (NASDAQ: AMZN), Apple Inc. (NASDAQ: AAPL), and C3.ai, Inc. (NYSE: AI).

The article continued: Seeing the extraordinary speed of AI’s advancements and impacts, combined with surging private- and public-sector demand, is causing regulators in the USA and EU to issue legislation calling for action. Now analysts are trying to determine whether the GenAI boom is setting up to be another bubble, or a legitimate long-term investment opportunity.
SCOPE AI PROVIDES CORPORATE UPDATE
Scope AI Corp. (CSE: SCPE) (OTCQB: SCPCF) (FSE: VN8) (“Scope” or the “Company”) today provided an update  on new developments of Scope’s artificial intelligence driven recognition technology called GEM (General Enterprise Machine Learning) system. Built on advanced visual recognition and neural network technology, GEM could advance industries, including Advertising and Gaming, by providing them with new insights and capabilities.
Advertising: GEM aims to enable advertising businesses to personalize ad content based on real-time user behavior analysis. By leveraging visual recognition technology, companies can create highly targeted and engaging ads, maximizing return on ad spend and driving customer engagement to new heights.
Gaming:  In the gaming industry, GEM aims to enhance user experiences by customizing gameplay and recommendations. By analyzing player behavior using neural networks, GEM provides customers and developers with invaluable insights with the intention of optimizing game design, increasing user retention, and maximizing revenue potential.
Unveiling Neural Networks: Neural networks are the foundation of GEM’s technology. These complex algorithms mimic the structure and functionality of the human brain, enabling machines to learn from vast amounts of data and make intelligent predictions and decisions. By harnessing the power of neural networks, GEM offers comprehensive capabilities in advanced pattern recognition, data analysis, and decision-making across industries.
“We’re very pleased at how seamless we were able to streamline, enhance, and strengthen our platform with the latest performance and security upgrades made to our infrastructure”, said Sean Prescott, Founder and Non-Executive Chairman of Scope AI. “The next generation of our platform will set us apart in the kind and sensitivity of data we can process and store. It’s a potential game-changer for the industry.”
Scope’s GEM platform includes advanced features designed to enhance user experience and security, all while streamlining operations. Built-in customer support and user management modules allow for seamless assistance, while the native referral system fosters user engagement and growth. Along with the full admin suite for comprehensive analysis and reporting, businesses are fully empowered with unparalleled capabilities and insights.
CONTINUED… Read this and more news for Scope AI at:  https://usanewsgroup.com/2024/04/26/the-currency-of-tomorrow-why-investing-in-cutting-edge-ai-recognition-tech-could-mean-big-money/
In other industry developments and happenings in the market this week include:
Meta Platforms, Inc. (NASDAQ: META), the parent company of Facebook, Instagram, and WhatsApp, recently teamed up with the Georgia Institute of Technology to create a massive open dataset to advance AI solutions for carbon capture, a technology with promising potential to address global climate concerns. As per the collaboration, Georgia Tech and Meta say their massive database could potentially make it easier and faster to design and implement new direct air capture technologies.
“The open-source database enabled the team to train an AI model that is orders of magnitude faster than existing chemistry simulations,” said Georgia Tech in a press release. “The project, named OpenDAC, could accelerate climate solutions the planet desperately needs.”
Researchers at Meta’s Fundamental AI Research (FAIR) team were already looking for ways to harness their machine-learning prowess to address climate concerns. They ultimately landed on direct air capture as what they believed to be a promising technology, and immediately reached out to Georgia Tech. FAIR’s lead authors generated the database by running quantum chemistry computations on inputs provided by Georgia Tech’s team, using about 400 million CPU hours along the way, and surpassing several hundreds of times more computing than the average academic computing lab can do in a year.
Amazon.com, Inc. (NASDAQ: AMZN) through its global Amazon Web Services (AWS) cloud system subsidiary recently rolled out its new AI system called Q, which it has dubbed as “the most capable generative artificial intelligence (AI)-powered assistant for accelerating software development and leveraging companies’ internal data.”
As well, Amazon also recently launched its Custom Model Import for Bedrock tool, which CEO Andy Jassy called a “sneak big launch as it satisfies a customer request we’ve heard frequently and that nobody has yet met.” The tool allows customers to import custom models they’ve built in Amazon SageMaker into tits Amazon Bedrock platform. Doing so lets enterprises utilize AI investments they’ve already made, while also leveraging Bedrock’s capabilities to scale their models and applications.
“Customers are excited about this, and as more companies find they’re employing a mix of custom-built models along with leveraging existing LLMs,” said Jassey. “The prospect of these two linchpin services in SageMaker and Bedrock working well together is quite appealing.”
Apple Inc. (NASDAQ: AAPL), whose iPhones currently hold the Top 4 (and 5 of the Top 10) best-selling smartphone models by sales, recently reported an all-time revenue record in sales in its most recent financial results. While being seen as potentially late to the game on AI, several reports in recent weeks has suggested that Apple is not only talking to OpenAI and/or Google about powering some of its AI features, it’s also been reportedly spending “millions of dollars a day” training its own AI model, called Ajax.
Now industry experts are saying the iPhone is about to become an “AI phone”, in anticipation of Apple’s upcoming iOS 18. A key anticipated feature of iOS 18 is Apple’s own large language model (LLM), similar to the technology behind AI chatbots like ChatGPT. It’s widely speculated that this Apple-developed LLM will be integrated with Siri, enhancing the capabilities of the iPhone’s digital assistant. As indicated by Bloomberg in late April, it’s suggested that Apple’s  LLM will be entirely on-device, meaning the tech will be powered inside by the iPhone’s processor, rather than in the cloud—which may be a bit less powerful and knowledgeable, but with far quicker response times.
C3.ai, Inc. (NYSE: AI), an Enterprise AI application software company, is actively working to enhance the petroleum industry in Houston, through a cooperative effort that allows oil and gas companies to share AI technology and applications with each other. This effort is meant to curb companies from withholding information from competitors, with the goal of collaboration instead.
“We’re building the applications that are, you know, monitoring every device on every offshore oil rig in real time so that they can see with 18 hours in advance before something fails and just shut it down,” said Tom Siebel, CEO of C3.ai. Siebel has explained that AI is at work in oil and gas, diagnosing issues and assisting with maintenance, giving the example of a giant like Shell uses AI to track their half a million valves around the world.
“They can see what’s going on,” said Siebel. “They can predict when a valve is going to be stuck open or closed before it happens, and if one of these valves gets stuck open or closed, things go real bad, real fast, right? And so, they’ve decided to make these applications available to Aramco, Eni, Chevron, Phillips.”
A recent report from Research and Markets predicted that the global AI in oil and gas market is expected to surge to an impressive $5.96 billion by 2028, growing at a CAGR of 13.3%.
Article Source: https://usanewsgroup.com/2024/04/26/the-currency-of-tomorrow-why-investing-in-cutting-edge-ai-recognition-tech-could-mean-big-money/
 CONTACT:USA NEWS [email protected](604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Scope AI Corp. advertising and digital media from the company directly. There may be 3rd parties who may have shares Scope AI Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Scope AI Corp. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Scope AI Corp. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/economic-shifts-ahead-as-ai-integrates-deeply-into-work-and-society-fueling-4-4-trillion-growth-302140422.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending